Pascal Biosciences is a biotechnology company focused on advancing innovative approaches for the treatment of cancer including cannabinoid-based therapeutics and targeted therapies. The company’s leading cannabinoid portfolio comprises a small molecule therapeutic, ST-403, that is advancing into clinical trials for the treatment of glioblastoma, and an immuno-stimulatory molecule. In addition, Pascal Biosciences is developing a B-cell targeted antibody for acute lymphoblastic leukemia and an antibody for calcium channels expressed by the immune system.
Pascal is headquartered in Vancouver, Canada. The company trades on the TSX Venture Exchange under the symbol “PAS”.
Company Details
- Founded
- -
- Address
- Seattle, Wa 98195, Us
- Industry
- Biotechnology
- Website
- pascalbiosciences.com
- HQ
- Seattle, WA
Pascal Biosciences Inc. Questions
Pascal Biosciences Inc.'s website is pascalbiosciences.com
Pascal Biosciences Inc.'s LinkedIn profile is https://ca.linkedin.com/company/pascal-biosciences-inc
Pascal Biosciences Inc.'s industry is
Biotechnology
Pascal Biosciences Inc.'s top competitors are
Wex Pharmaceuticals Inc.,
Adaptive Biotechnologies Corp.,
Primary Peptides,
Parse Biosciences,
Xenon Pharmaceuticals Inc.,
Mydecine Innovations Group,
Sirona Biochem Corp.,
Nanovation Therapeutics™,
Presage Biosciences, Inc.,
Abbiosci Inc.
Pascal Biosciences Inc.'s categories are Biotechnology
Pascal Biosciences Inc.'s founding year is 2013
